The link between hearing loss and dementia is real, measurable, and frankly, one of the most significant findings in preventive neurology in the past decade. Untreated hearing loss in midlife is now recognised as the single largest modifiable risk factor for dementia—larger than smoking, hypertension, or physical inactivity according to the 2020 Lancet Commission report. The question everyone actually wants answered is simpler: if I get hearing aids, will they protect my brain? The honest answer is we’re getting closer to yes, but it’s more nuanced than a marketing brochure will tell you.
What the Lancet Commission Actually Found
The 2020 Lancet Commission on Dementia Prevention, Intervention, and Care identified twelve modifiable risk factors across the lifespan. Hearing loss in midlife (ages 45–65) accounted for approximately 8% of dementia risk—the highest attributable fraction of any single factor they examined. To put that in context, that’s more than diabetes (3%), smoking (2%), or depression (4%). The updated 2024 report reinforced these findings and added that even mild hearing loss (25–40 dB HL) carries increased risk.
This isn’t speculative. The data comes from large population studies tracking hundreds of thousands of people over decades. The association is dose-dependent: the worse your hearing loss, the higher your dementia risk. Mild hearing loss roughly doubles your risk. Moderate loss triples it. Severe untreated hearing loss gives you up to five times the risk of someone with normal hearing.
Why Hearing Loss Might Accelerate Cognitive Decline
The mechanisms aren’t completely understood, but there are three leading theories, and they’re likely all operating simultaneously.
Cognitive load theory suggests that when your brain has to work overtime to decode degraded auditory signals, it diverts resources away from other cognitive tasks like working memory and processing speed. Imagine running background software that constantly drains your battery—that’s what untreated hearing loss does to your cognitive reserves. After years of this, the compensatory systems break down. We see this in clinic constantly: patients who’ve been “getting by” for five or ten years come in exhausted, not just from conversation but from the sheer mental effort of listening. Their working memory scores on standardised testing are often significantly below age norms, and they frequently attribute it to “getting old” when it’s actually auditory deprivation.
Social isolation is the second pathway. Hearing loss makes social engagement difficult, so people withdraw. They stop going to dinners, church, community groups—all the activities that provide cognitive stimulation and emotional connection. The research on social isolation and dementia is unambiguous: chronic loneliness and lack of social engagement are independent risk factors for cognitive decline. We’ve all had patients who’ve pulled back from life because the effort of keeping up in group conversation became unbearable. The tragedy is they often don’t realise how much they’ve withdrawn until they’re fitted with properly programmed hearing aids and suddenly reconnect.
Structural brain changes are the third mechanism. Neuroimaging studies show that prolonged auditory deprivation leads to atrophy in the auditory cortex and associated brain regions. Use it or lose it applies to neural pathways. When auditory input decreases, the brain reorganises—and not in a good way. Some височal lobe regions associated with both hearing and memory shrink measurably over time in people with untreated hearing loss. Whether this is reversible with intervention isn’t fully known, which is why early treatment matters.
The ACHIEVE Trial: Does Treatment Actually Help?
For years, the elephant in the room was this: we knew hearing loss and dementia were linked, but we didn’t know if treating hearing loss would reduce dementia risk. Association doesn’t prove causation. Maybe people destined to develop dementia just happen to lose hearing earlier. Maybe there’s a common underlying cause we haven’t identified.
The ACHIEVE trial, published in *The Lancet* in 2023 by Frank Lin and colleagues, was the first large-scale randomised controlled trial designed to answer this question. They recruited 977 adults aged 70–84 with untreated hearing loss and randomly assigned them to either hearing aid intervention or a control group (health education). The primary outcome was change in cognitive function over three years.
The results were mixed but ultimately encouraging. In the full sample, there wasn’t a statistically significant difference in cognitive decline between groups. But—and this is critical—in the pre-specified subgroup of participants at higher baseline risk for cognitive decline, hearing aid use was associated with a 48% reduction in cognitive decline over three years. That’s a clinically meaningful difference.
The trial had limitations. Three years may not be long enough to detect effects on dementia incidence. Compliance varied—not everyone wore their aids consistently. And the intervention was excellent (participants received best-practice audiological care with Real Ear Measurement verification and regular follow-up), which isn’t representative of what happens in many retail hearing aid settings.
What This Means in Practical Terms
First, this isn’t about fear-mongering people into buying hearing aids. The research tells us that untreated hearing loss is bad for your brain, but treating it isn’t a guaranteed shield against dementia. Think of it more like managing blood pressure or cholesterol—you’re reducing risk, not eliminating it.
Second, not all hearing aid fittings are equal. The ACHIEVE trial used gold-standard fitting protocols: Real Ear Measurement to verify that prescribed gain actually reaches the eardrum, validated outcome measures, and structured follow-up. In our practice, we use REM on every fitting because we know from decades of research (and frankly, from seeing patients fitted elsewhere) that default manufacturer settings often under-amplify by 10–15 dB in the frequencies that matter most for speech understanding. If your aids aren’t providing adequate audibility, they’re not giving your brain the input it needs.
Third, timing matters. The Lancet data points to midlife hearing loss as the critical window. If you’re noticing difficulty in background noise, asking people to repeat themselves, or turning the TV up, get a diagnostic hearing assessment—pure tone audiometry, speech-in-noise testing, tympanometry. Not a free screening at a shopping centre kiosk. A proper assessment. In Australia, eligible pensioners can access services through the Hearing Services Program (formerly known as the voucher scheme). Private health funds typically provide $500–$2500 per aide depending on your level of cover. DVA covers eligible veterans fully.
Fourth, the goal isn’t perfect hearing—it’s maintaining cognitive engagement. We see patients in their seventies and eighties make remarkable turnarounds when they start wearing well-fitted aids consistently. They rejoin conversations, go back to social activities, report feeling mentally sharper. That’s the point. We’re not chasing audiometric perfection; we’re trying to keep your brain active and connected.
The State of the Science: What We Know and Don’t Know
We know the association between hearing loss and dementia is robust and biologically plausible. We know the mechanisms are likely multifactorial. We’re starting to have evidence that intervention helps, at least in higher-risk populations, but we need longer-term data and more trials.
What we don’t know yet is whether there’s a threshold effect—does treating mild loss provide the same benefit as treating moderate or severe loss? We don’t know the minimum “dose” of hearing aid use required (though the ACHIEVE data suggests consistent daily wear matters). We don’t know if there’s an age beyond which intervention is less effective, though there’s no reason to think hearing aids stop being useful in very old age.
What You Should Do
If you’re over 50 and suspect you have hearing loss, get tested. A baseline audiogram gives you a reference point. If you have measurable loss—even mild loss in the speech frequencies (500–4000 Hz)—consider treatment, especially if you’re noticing functional impacts: difficulty in groups, avoiding social situations, cranking up the volume, missing conversation in noise.
If you’ve been putting off hearing aids because “it’s not that bad yet,” understand that waiting doesn’t help. The brain changes associated with auditory deprivation accumulate over time. Early intervention is easier—both in terms of adjustment to amplification and potentially in terms of preserving cognitive function.
And if you already have hearing aids but rarely wear them, or they’re sitting in a drawer because they “don’t work,” get back to your audiologist for reprogramming or reassessment. Poorly fitted or under-amplified aids won’t give you the benefit you need. Verify that Real Ear Measurement was used. Ask about your speech-in-noise performance. Make sure you’re getting structured follow-up, not just a handshake and a see-you-in-three-years.
The research is still evolving, but the direction is clear: your hearing health is your brain health. Treating hearing loss won’t guarantee you’ll never develop dementia, but leaving it untreated significantly increases your risk of cognitive decline. That’s not marketing fluff. That’s what the data shows.
